MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ
1.000
+0.018
+1.87%
After Hours: 1.050 +0.05 +5.00% 18:52 12/02 EST
OPEN
0.9650
PREV CLOSE
0.9816
HIGH
1.029
LOW
0.9650
VOLUME
99.08K
TURNOVER
0
52 WEEK HIGH
4.076
52 WEEK LOW
0.9244
MARKET CAP
74.41M
P/E (TTM)
-2.1200
1D
5D
1M
3M
1Y
5Y
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that managemen...
ACCESSWIRE · 11/23 13:00
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that managemen...
ACCESSWIRE · 11/09 13:00
BRIEF-Pieris Pharmaceuticals Reports Quarterly Loss Per Share Of $0.13 - Filing
Reuters · 11/02 11:57
Recap: Pieris Pharmaceuticals Q3 Earnings
Benzinga · 11/02 11:52
Pieris Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $5.37M beats by $0.86M
Seekingalpha · 11/02 11:11
Pieris Pharmaceuticals Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $5.37M Beat $2.26M Estimate
Benzinga · 11/02 11:05
-- Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Reports Q3 Revenue $5.4M
-- Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Reports Q3 Revenue $5.4M
MT Newswires · 11/02 07:25
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...
ACCESSWIRE · 10/26 12:00
More
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.